Author Archive | StuChapman

Combination Therapies Dominate the Agenda of the Worldwide Meeting

The world of oncology once again convened in Chicago for our annual gathering aimed at conquering cancer and celebrating new developments, which are coming ever faster and more furious. Although once considered almost taboo in RCC, many of the most intriguing presentations and abstracts from the American Society of Clinical Oncology’s (ASCO) annual meeting focused […]

Continue Reading

Sunitinib and Zoledronic Acid
Combination Therapy for Metastatic
Renal Cell Carcinoma: Alarming for Osteonecrosis of the Jaw

Introduction As medical treatment of serious diseases such as cancer lengthens patient survival, the side effects of new drugs are beginning to present in community dentists’ patients. The most well-known example is probably bisphosphonate-related osteonecrosis of the jaw (ONJ), which was first reported in 36 patients in 2003 by Marx1; all 36 patients had been […]

Continue Reading

Cardiovascular Events and Torsades
de Pointes in Patients Using Pazopanib
and Other Marketed Anti-VEGF Agents
for Metastatic Renal Cell Carcinoma:
A Descriptive Study

Sumitra Shantakumar1, Samantha St. Laurent2, Myrthe van Herk-Sukel3, Jeanenne J. Nelson4 Affiliations: 1GlaxoSmithKline, Worldwide Epidemiology, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Worldwide Epidemiology, Waltham, MA, USA; 3PHARMO Institute for Outcomes Research, Utrecht, Netherlands; 4GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania, 19426-0989, United States Summary Pazopanib is an angiogenesis inhibitor approved by the FDA in 2009 for metastatic renal cell carcinoma […]

Continue Reading

Optimizing the Safety Profile of
Immune Checkpoint Blockade in
Renal Cell Carcinoma

Martin H. Voss, MD Assistant Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York   In this review, current information on the diagnosis, monitoring, and management of immune-related adverse reactions of anti-PD-1 antibody therapy is presented. Recent literature highlights optimal strategies for managing specific adverse events related to antibodies that target […]

Continue Reading